I learned of this years ago and I’m very
glad to see it becoming a reality
Japanese researchers, led by Dr. Katsu Takahashi, are poised to conduct the world’s first clinical trials of a groundbreaking tooth regrowth medicine at Kyoto University Hospital. This innovative treatment targets the USAG-1 protein, which naturally inhibits the development of a third set of teeth that humans possess but rarely develop.
The research is grounded in evidence suggesting the existence of dormant buds for a third dentition. Approximately 1% of individuals exhibit hyperdontia, characterized by the presence of extra teeth, which researchers believe represents this third set. In animal trials, the medicine demonstrated remarkable success in generating new teeth in mice, ferrets, and dogs, without causing significant side effects.
Currently, Phase 1 trials are underway to assess the safety of the medicine in healthy adults with at least one missing tooth. Phase 2 trials, scheduled for 2025, will focus on children aged 2 to 7 with congenital tooth agenesis. If successful, this treatment could revolutionize the dental landscape by offering a “third choice” alongside dentures and implants for individuals with missing teeth. The potential public access to this treatment is anticipated by 2030. 👈

